Dynavax Technologies (NASDAQ:DVAX) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a hold rating to a buy rating in a research note released on Tuesday morning.

Separately, HC Wainwright increased their price target on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $12.48 on Tuesday. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 96.01 and a beta of 1.34. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.41. The stock’s 50 day moving average price is $12.76 and its two-hundred day moving average price is $11.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently modified their holdings of DVAX. GAMMA Investing LLC raised its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE raised its position in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies during the third quarter worth approximately $45,000. Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies during the third quarter worth approximately $89,000. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.